Mike Clark's List of Publications

Some of my most recent publications are available as pre-prints or re-reprints and are listed elsewhere on my website. The following list is a more comprehensive list of publications going back to 1980.

 Section A: Original publications in refereed journals


Clark,M.R., & Milstein,C. Som. Cell Genet. 7, 657-666 (1981) Expression of spleen cell immunoglobulin phenotype in hybrids with myeloma cell lines.


Clark,M.R. Ph.D. Thesis. University of Cambridge (1982) Antibodies in somatic cell hybrids.


Butcher,G.W., Diamond,A.G., Clark,M.R., & Howard,J.C. Transplant. Proc. 15, 1573-1577 (1983) Similarity of RT1D beta chains from independent rat haplotypes.

Hoang,T., Gilmore,D., Metcalf,D., Cobbold,S., Watt,S., Clark,M., Furth,M., & Waldmann,H. Blood 61, 580-588 (1983) Separation of hemopoietic cells from adult mouse marrow by use of monoclonal antibodies.

Watt,S.M., Metcalf,D., Gilmore,D.J., Stenning,G.M., Clark,M.R., Waldmann,H. Mol. Biol. Med. 1, (1983) Selective isolation of murine erythropoetin-responsive progenitor cells (CFU-E) with monoclonal antibodies.


Aqel,N.M., Clark,M., Cobbold,S.P., & Waldmann,H. J. Immunol. Meth. 69, 207-214 (1984) Immunohistological screening in the selection of monoclonal antibodies: the use of isotype-specific antiglobulins.

Clark,M.R., Cobbold,S.P., Waldmann,H., & Coombs.R.R.A. J. Immunol. Meth. 66, 81-87 (1984) Detection of monoclonal antibodies against cell surface antigens: the use of antiglobulins coupled to red blood cells.

Watt,S.M., Gilmore,D.J., Clark,M.R., Davies,J.M., Swirsky,D.M., & Waldmann,H. Mol. Biol. Med. 2, 351- 368 (1984) Haemopoetic progenitor cell heterogeneity revealed by a single monoclonal antibody YW 13.1.1.


Bindon,C.I., Hale,G., Clark,M.R. &, Waldmann,H. Transplantation 40, 538-544 (1985) Therapeutic potential of monoclonal antibodies to the leukocyte common antigen: Synergy and interference in complement-mediated lysis.

Hale,G., Clark,M., & Waldmann,H. J. Immunol. 134, 3056-3061 (1985) Therapeutic potential of rat monoclonal antibodies: Isotype specificity of antibody-dependant cell-mediated cytotoxicity with human lymphocytes.


Benjamin,R.J., Cobbold,S.P., Clark,M.R., & Waldmann,H. J. Exp. Med. 163, 1539-1552 (1986) Tolerance to rat monoclonal antibodies: implications for serotherapy.


Aqel,N.M., Clark,M., Jones,D.B., Arno,J., & Waldmann,H. J. Path. 152, 265-273 (1987) Identification of cells of the human mononuclear phagocyte system with rat monoclonal antibodies.

Bruggemann,M., Williams,G.T., Bindon,C.I., Clark,M.R., Walker,M.R., Jefferis,R., Waldmann,H., & Neuberger,M.S. J. Exp. Med. 166, 1351-1361 (1987) Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

Clark,M.R., & Waldmann,H. JNCI 79, 1393-1401 (1987) T-cell killing of target cells induced by hybrid antibodies: Comparison of two bispecific monoclonal antibodies.

Tighe,H., Clark,M., & Waldmann,H. Transplantation 44, 818-823 (1987) Blocking of cytotoxic T cell function by monoclonal antibodies against the CD45 antigen (T200/leukocyte-common antigen).

Welsh,C.J.R., Steinitz,M., Clark,M.R., & Coombs,R.R.A. J. Immunol. Meth. 104, 271-274 (1987) The detection of heat-aggregated IgG (as a model for immune complexes) by reverse passive haemagglutination using a human monoclonal rheumatoid factor coupled to erythrocytes.


Gilliland,L.K., Clark,M.R., & Waldmann,H. Proc. Natl. Acad. Sci. USA 85, 7719-7723 (1988) Universal bispecific antibody for targeting tumour cells for destruction by cytotoxic T cells.

Hale,G., Dyer,M.J.S., Clark,M.R., Phillips,J.M., Marcus,R., Riechmann,L., Winter,G., & Waldmann,H. Lancet 2, 1394-1399 (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.

Riechmann,L., Clark,M.R., Waldmann,H., & Winter,G. Nature 332, 323-327 (1988) Reshaping human antibodies for therapy.

Watt,S.M., Gilmore,D.J., Davis,J.D., Clark,M.R., & Waldmann,H. Molecular and Cellular Probes 1, 297- 326 (1988) Cell surface markers on haemopoietic precursors. Reagents for the isolation and analysis of progenitor cell populations.


Bruggemann,M., Teale,C., Bindon,C., Clark,M., & Waldmann,H. J. Immunol. 142, 3145-3150 (1989) A matched set of rat/mouse chimeric antibodies.

Clark,M., Bindon,C., Dyer,M., Friend,P., Hale,G., Cobbold,S., Calne,R., & Waldmann,H. Eur. J. Immunol. 19, 381-388 (1989) The improved lytic function and in-vivo efficacy of monovalent monoclonal CD3 antibodies.


Cobbold,S.P., Rebello,P.R.U.B., Davies,H.ff.S., Friend,P.J. & Clark,M.R. Meth. Enzymol. 127, 19- 24 (1990) A simple method for measuring patient antiglobulin responses against isotypic or idiotypic determinants.

Mathieson,P.W., Cobbold,S.P., Hale,G., Clark,M.R., Oliveira,D.B.G., Lockwood,C.M. & Waldmann,H. New England Journal of Medicine 323, 250-254 (1990) Monoclonal antibody therapy in systemic vasculitis.


Gorman,S.D., Clark,M.R., Routledge,E.G., Cobbold,S.P. & Waldmann,H. P.N.A.S. 88, 4181-4185 (1991) Reshaping a therapeutic CD4 antibody.

Routledge, E.G., Lloyd, I., Gorman, S., Clark, M. & Waldmann, H. Eur. J. Immunol. 21, 2717-2725 (1991) A humanized monovalent CD3 antibody which can activate homologous complement.

Haagen,I.A., van de Griend,R., Clark,M., Geerars,A., Bast,B. & de Gast,B. Clinical and Exp. Immunol. 90, 368-375 (1992) Killing of human leukemia lymphoma B-cells by activated cytotoxic T-lymphocytes in the presence of a bispecific monoclonal-antibody (CD3/CD19)


Isaacs, J.D., Clark, M.R., Greenwood, J. & Waldmann, H. J. Immunol 148, 3062-3071 (1992) Therapy with monoclonal antibodies - an in vivo model for the assessment of therapeutic potential


Bolt,S., Routledge,E., Lloyd,I., Chatenoud,L., Pope,H., Gorman,S.D., Clark,M. & Waldmann,H. Eur. J. Immunol. 23, 403-411 (1993) The generation of a humanised, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

Dunne,D.W., Richardson,B.A., Jones,F.M., Clark,M., Thorne,K.J.I. & Butterworth,A.E. Parasite Immunology 15, 181-185 (1993) The use of mouse/human chimaeric antibodies to investigate the roles of different antibody isotypes, including IgA2, in the killing of Schistosoma mansoni schistosomula by eosinophils

Greenwood,J., Clark,M. & Waldmann,H. Eur. J. Immunol. 23, 1098-1104 (1993) Structural motifs involved in human IgG antibody effector functions


Abbs,I.C., Clark,M., Waldmann,H., Chatenoud,L., Koffman,C.G. & Sacks,S.H. Therapeutic Immunology 1, 325-331 (1994) Sparing of the first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.

Haagen, I.A., de Lau, W., Bast, B.J.E.G., Geerars, A.J.G., Clark, M.R. & de Gast, B.C. Cancer Immunology and Immunotherapy 39: 391-396 (1994) Unprimed CD4+ and CD8+ T-cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic

Haagen,I-A., Geerars,A., de Lau,W., Clark,M., van de Griend,R., Bast,B., & de Gast,B. Blood 84, 556- 563 (1994) Killing of autologous B-lineage malignancy using CD3xCD19 bispecific monoclonal antibody in end stage leukemia and lymphoma


de Gast,G.C., Haagen,I-A., van Houten,A.A., Klein,S.C., Duits,A.J., de Weger,R.A., Vroom,T.M., Clark,M.R., Phillips,J., van Dijk,A.J.G., de Lau,W.B.M. & Bast,B.J.E.G. Cancer Immunol Immunother 40, 390-396 (1995) CD8 T cell activation after intravenous administration of CD3xCD19 bispecific antibody in patients with non-Hodgkin lymphoma

de Gast,G.C., van Houten,A.A., Haagen,I-A., Klein,S.C., de Weger,R.A., van Dijk,A.J.G., Phillips,J., Clark,M.R. & Bast,B.J.E.G. J. Hematotherapy 4, 433-437 (1995) Clinical Experience with CD3xCD19 Bispecific Antibodies in patients with B-cell malignancies

Haagen,I-A., Geerars,A.J.G., Clark,M.R., & van de Winkel,J.G.J. Journal of Immunology 154, 1852-186 (1995) Interaction of human monocyte Fc gamma receptors with rat IgG2b: A new indicator for the Fc gamma RIIA (R-H131) polymorphism


McElveen,J., Clark,M.R., Smith,S.J., Sewell,H.F. & Shakib,F. , Clin Exp Allergy 28, 1427-1434 (1998) Primary sequence and molecular model of the variable region of a mouse monoclonal anti-Der p I antibody showing a similar epitope specificity as human IgE.

Redpath,S., Michaelsen,T., Sandlie,I., & Clark,M.R. , Immunology 93, 595-600 (1998) Activation of complement by human IgG1 and human IgG3 antibodies against the human leucocyte antigen CD52

Redpath,S., Michaelsen,T.E., Sandlie,I., & Clark, M.R. , Human Immunology 59, 720-727 (1998) The influence of the hinge region length in binding of human IgG to human Fc gamma receptors.


Armour, K.L., Clark, M.R., Hadley, A.G., & Williamson L.M. , Eur J Immunol, 29, 2613-2624 (1999) Recombinant human IgG molecules lacking Fc-gamma RI binding and monocyte triggering activities

Furmonaviciene, R., Tighe, P.J., Clark, M.R., Sewell, H.F., & Shakib, F. Clin Exp Allergy 29, 1563-1571 (1999), The use of phage-peptide libraries to define the epitope specificity of a mouse monoclonal anti-Der p 1 antibody representative of a major component of the human IgE anti-Der p 1 response.

Watkins, N.A., Armour, K.L., Smethurst, P.A., Metcalfe, P., Scott, M.L., Hughes, D.L., Smith, G.A., Williamson, L.M., Clark, M.R., & Ouwehand, W.H. Transfusion 39, 781-789 (1999), Rapid human platelet antigen-1a phenotyping using either diabody based haemagglutination or recombinant IgG1 based assays.


Atherton, A., Armour, K.L., Bell, S., Minson, A.C., & Clark, M.R. Eur J. Immunol. (2000) 30: 2540-547 The Herpes Simplex Virus Type 1 Fc Receptor Discriminates between IgG1 Allotypes

Clark, M Immunology Today (2000) 397, 355-412 Antibody humanisation: a case of the 'Emperor's new clothes'?

Garner, S.F., Smethurst, P.A., Merieux, Y., Aeby, C., Smith G., Armour, K.L., Scott, M.L., Williamson, L.M., Metcalf, P. Goodall, A.H., Clark, M.R., Rigal, D., Schawaller, M. & Ouwehand, W.H. British Journal of Haematology (2000) 108, 440-447 A rapid one-stage whole-blood HPA-1a phenotyping assay using a recombinant monoclonal IgG1 anti-HPA-1a

Jaakkola, K., Nikula, T., Holopainen, R., Vahasilta, T., Matikainen, M-T., Laukkanen, M-L., Huupponen, R., Halkola, L., Nieminen, L., Hiltunen, J., Parviainen, S., Clark, M.R., Knuuti, J., Savunen, T., Kaapa, P., Voipio-Pulkki, L.M., & Jalkanen, S. American Journal of Pathology (2000) 157, 463-471 In Vivo Detection of Vascular Adhesion Protein-1 in Experimental Inflammation

McElveen, J.E., Furtado, P.B., Smith, S.J., Clark, M.R., Spendlove, I., Sewell, H.F., & Shakib, F. J Clin Pathol: Mol Pathol (2000) 53, 77-82 Characterisation of a mouse monoclonal anti-idiotype reactive with a V-region sequence commonly used by human immunoglobulins.


Armour, K.L., Atherton, A., Williamson, L.M. & Clark, M.R. Biochem Soc Trans (2002) 30, 495-500 The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors

Furtado, P.B., McElveen, J.E., Gough, L., Armour, K.L., Clark, M.R., Sewell, H.F., & Shakib, F. J. Clin Pathol: Mol Pathol (2002) 55, 315-324 The production and characterisation of a chimaeric human IgE antibody, recognising the major mite allergen Der p 1, and its chimaeric human IgG1 anti-idiotype


Armour, K.L., van de Winkel, J.G.J., Williamson, L.M., & Clark, M.R. Molecular Immunology (2003) 40: 585-593 Differential binding to human Fc-gamma-RIIa and Fc-gamma-RIIb receptors by human IgG wildtype and mutant antibodies


Joutsi-Korhonen, L., Preston, S., Smethurst, P.A., Ijsseldijk, M., Schaffner-Reckinger, E., Armour, K.L., Watkins, N.A., Clark, M.R., de Groot, P.G., Farndale, R.W., Ouwehand, W.H., & Williamson, L.M. Thrmobosis and Haemostasis (2004) 91: 743-754 The effect of recombinant IgG antibodies against the leucine-33 form of the platelet beta 3 integrin (HPA-1a) on platelet function


Kirton, C. M., Laukkanen, M-L., Nieminen, A., Merinen, M., Stollen, C., Armour, K., Smith, D.J., Salmi, M., Jalkanen, S., & Clark, M.R. Eur. J. Immuno. (2005) 35: 3119-3130 Function-blocking antibodies to human vascular adhesion protein-1: A potential anti-inflamatory therapy

Shankar, V., Kools, J.J., Armour, K.L. & Clark, M.R. Hybridoma (2005) 24: 50-54 A chimeric antibody to varicella-zoster virus glycoprotein E


Armour, K.L., Parry-Jones, D.R., Beharry, N., Ballinger, J.R., Mushens, R., Williams, R.K., Beatty, C., Stanworth, S., Lloyd Evans, P., Scott, M., Clark, M.R., Peters M, & Williamson, L.M. Blood (2006) 107: 2619-2626 Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity


Wiggington, S.J., Furtado, P.B., Armour, K.L., Clark, M.R., Robins, A., Emara, M., Ghaemmaghami, A.M., Sewell, H.F., & Shakib, F. Clinical and Experimental Allergy (2007) 38: 313-319 An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotype inhibits basophil degranulation through cross-linking of FceRI with FcgRIIb Goodman, R.S., Kirton, C.M., Oostingh, G.J., Sch�n, M.P., Clark, M.R., Bradley, J.A., & Taylor,�C.J. Transplantation (2008) 85: 471-477 PECAM-1 polymorphism affects monocyte adhesion to endothelial cells


Ghevaert, C., Wilcox, D.A., Fang, J., Armour, K.L., Clark, M.R., Ouwehand, W.H., & Williamson,�L.M. Journal of Clinical Investigation (2008) 118: 2929-2938 Developing recombinant HPA-1a-specific antibodies with abrogated Fc-gamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia


Armour, K.L., Smith, C.S. & Clark, M.R. J. Immunol. Meth. (2010) 354: 20-33 Expression of human FcgRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding

 Section B: Reviews, books and editorials


Milstein,C., Clark,M.R., Galfre,G., & Cuello,A.C. Immunol. 80, Progress in Immunol. IV (Ed. Fougereau, M. & Dausset, J.) Pub. Academic press, London (1980) Monoclonal antibodies from hybrid myelomas.


Clark,M.R. La Ricerca Clin. Lab. 11, 195-203 (1981) Monoclonal antibodies derived from hybrid myelomas.

Galfre,G., & Clark,M.R. Monoclonal Antibodies and Developments in Immunoassay (Ed. Albertini, A. & Ekins, R.) Pub. Elsevier/ North-Holland (1981) Strategies in the derivation of hybrid myelomas.


Clark,M., Cobbold,S., Hale,G., & Waldmann,H. Immunol. Today 4, 100-101 (1983) Advantages of rat monoclonal antibodies.


Waldmann,H., Cobbold,S., Wilson,A., Clark,M., Watt,S., Hale,G., & Tighe,H. Advan. Exp. Med. Biol. 186, 869-878 (1985) Rat monoclonal antibodies for bone marrow transplantation - the CAMPATH series.


Clark,M., & Waldmann,H. Methods in Hematology 13, 1-20 (1986) Production of murine monoclonal antibodies.

Clark,M.R. Revisiones Sobre Biologia Celular 9, 1-61 (1986) Medical applications of monoclonal antibodies.

Clark,M.R. Meth. Enzymol. 121, 548-556 (1986) The detection and characterization of antigen-specific monoclonal antibodies using anti-immunoglobulin isotype antibodies coupled to red blood cells.


Clark,M., Gilliland,L., & Waldmann,H. Progress in Allergy 45, 31-49 (1988) Hybrid antibodies for therapy.

Waldmann,H., Hale,G., Clark,M., Cobbold,S., Benjamin,R., Friend,P., Bindon,C., Dyer,M., Qin,S., Bruggemann,M., Tighe,H. Progress in Allergy 45, 16-30 (1988) Monoclonal antibodies for immunosuppression.


Hale,G., Bindon,C., Clark,M., Dyer,M., & Waldmann,H. Actua Sandoz 14, 30-41 (1989) Complement activation by monoclonal antibodies.


Clark,M., Bolt,S., Tunnacliffe,A., & Waldmann,H. Bispecific antibodies and targeted cellular cytotoxicity: Second international conference. (Ed. Romet-Lemonne,J.L., Fanger,M.W. & Segal,D.M.), pp 243-247 (1990) Use of bispecific monoclonal antibodies to treat hematological malignancies: a model system using CD3 transgenic mice.

Cobbold, S.P., Hale, G., Clark, M.R. & Waldmann,H. Prog. Clin. Biol. Res. 333, 139-151 (1990) Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.

Gorman,S.D, & Clark,M.R. Seminars in Immunology 2, 457-466 (1990) Humanisation of monoclonal antibodies for therapy.

Waldmann, H., Cobbold, S., Clark, M., Hale, G., Qin, S. & Wise, M. Horizons in Medicine (Ed. Borysiewicz) (1990) The generation of immunological tolerance as a therapeutic procedure.

Waldmann,H., Hale,G., Cobbold,S.P., Clark,M., Qin,S., Benjamin,R., & Dyer,M.S. Hematology 12, 277- 293 (1990) Monoclonal antibody therapy to prevent graft versus host disease.


Clark,M. (Editor) Protein engineering of antibody molecules for prophylactic and therapeutic applications in man. Pub. Academic Titles, UK(1993) pp. 1-9 General Introduction.

Routledge,E., Gorman,S., & Clark,M. Protein engineering of antibody molecules for prophylactic and therapeutic applications in man. (Ed. Clark,M. ) Pub. Academic Titles, UK (1993) pp. 13-44 Reshaping of antibodies for therapy.

Greenwood,J.D., & Clark,M. Protein engineering of antibody molecules for prophylactic and therapeutic applications in man. (ed. Clark,M. ) Pub. Academic Titles, UK (1993) pp 85-100 Effector functions of matched sets of recombinant IgG subclass antibodies.


Clark,M Trends in Cell Biology 4, 70 (1994) "Not immune to competition." Book review of 'Principles of Cellular & Molecular Immunology' by Austyn,J.M., & Wood,K.I.

Routledge,E.D. Gorman,S. & Clark,M.R. Cell and Tissue Culture: Laboratory Procedures (Ed. Griffiths,J.B., Doyle,A. & Newell,D.G.) Pub. John Wiley & Sons Ltd. (1994) Module 27F:0.1-23 Recombinant Monoclonal Antibodies - an Overview


Clark,M. Monoclonal Antibodies; Principles and Applications. (ed. Birch,J.R. & Lennox,E.S.) Pub. John Wiley, New York (1995) pp 1-43 General Introduction.

Clark,M. Immunology Today 16, 410-411 (1995) A book review of 'Opal Module 3: Immune Cells', edited by H-P. Hartung and X. Zhang


Clark,M. Immunology Today 17, 52 (1996) Update: Immunology Web Links

Clark,M. Immunology Today 17, 251 (1996) Two different roles for the neonatal IgG Fc receptor FcRn

Clark,M. Lancet 347, 1104 (1996) One IgG receptor, two different functions


Clark,M. Chemical Immunology 65, 88-110 (1997) IgG Effector Mechanisms

Clark,M. Antibody Therapeutics (Ed. Harris, W.F. & Adair, J. ) Pub. CRC Press Inc. (1997) pp 3-31 Unconjugated antibodies and therapeutics

Clark,M. Genetics of Common Diseases: Future therapeutic and diagnostic possibilities. (Ed. Day, I.M.N. & Humphries, S.E.) Pub. Bios Scientific Publishers (1997), pp 285-306 Protein engineering of therapeutic antibodies: use of antibodies for immunosuppression and treatment of leukaemias


Clark,M. Immunology Today 20, 56 (1999), A Review of "Immunology Interactive 2.0"


Clark, M. The Lancet (2000) 355, 1557 Chimeric and humanised - misunderstood


Clark, M Basic Biotechnology: (2001) 2nd Edition. (Ed. C. Ratladge & B. Kristiansen) Pub. Cambridge University Press (2001) pp 503-530 Immunochemical Applications


Clark, M. The Biochemist (2002) 24:4, 48-49 Obituary: C�sar Milstein (1927-2002)


Clark, M Nature Biotech (2005) 23: 1047-1049 Empowering the inventor - the case of monoclonal antibodies


Clark, M. Basic Biotechnology: 3rd Edition. (Ed. C. Ratladge & B. Kristiansen) Pub. Cambridge University Press (2006) pp 627-655 Immunochemical Applications

Clark, M. Times Higher Education Supplement (2006) 30th March Clinical Trials and Tribulations


Clark, M., Colombel, J-F., Feagan, B.C., Fedorak, R.N., Hanauer, S.B., Kamm, M.A., Mayer, L., Reguiro, C., Rutgeerts, P., Sandborn, W.J., Sands, B.E., Schreiber, S., Targan, S. Travis, S. & Vermeire, S. Gastroenterology (2007) 133: 312-339 American Gastroenterological Association consensus development conference on the use of biologics in the treatment of Inflammatory Bowel Disease, June 21-23, 2006

Clark, M. in Waldmann, H. (ed.), Monoclonal Antibodies as Therapeutic Agents: Fundamentals, Therapeutic Applications and Latest Advances, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (2007) (online at http://www.hstalks.com/?t=BL0471360-Clark) "Antibody Engineering of Fc Effector Functions"

Clark, M. in Waldmann, H. (ed.), Monoclonal Antibodies as Therapeutic Agents: Fundamentals, Therapeutic Applications and Latest Advances, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (2007) (online at http://www.hstalks.com/?t=BL0471316-Clark) "Fc Receptors and Antibody Effector Functions"

 Section C: UK Patent Filings

A number of the projects have led to the development of potentially useful therapeutic reagents. Various licensing agreements have been entered into and where appropriate patent protection has been sought. Although patents have been filed internationally only the U.K. priority filings are listed below.
  1. Cobbold,S.P., Clark,M.R., Benjamin,R.J. & Waldmann,H. Priority date 2/4/86 Application 8608068 (U.K.) Monoclonal antibodies and their use.
  2. Clark,M.R., & Waldmann,H. Priority date 5/11/86 Application 8626412 (U.K.) Antibodies.
  3. Gilliland,L.K., Clark,M.R. & Waldmann,H. Priority date 5/11/86 Application 8626413 (U.K.) Antibodies.
  4. Waldmann,H., Clark,M.R., Winter,G.P. & Riechmann,L. Priority date 12/2/88 Application 8803228 (U.K.) Priority date 25/2/88 Application 8804464 (U.K.) Improvements in or relating to antibodies.
  5. Gorman,S.D., Clark,M.R., Cobbold,S.P., & Waldmann,H. Priority date 17/9/90 Application 90202823.1 (U.K.) Altered antibodies and their preparation.
  6. Clark,M.R. Priority date 12/3/91 Application 9105245.6 (U.K.) Binding molecules.
  7. Routledge,E.D., Bolt,S., Clark,M.R., Gorman,S.D., & Waldmann,H. Priority date 24/3/92 Application 9206422.9 (U.K.) Improved humanised CD3 antibodies
  8. Clark,M.R. Priority date 8/93 Binding molecules.
  9. Armour,K., Williamson,L., & Clark,M.R. Priority date 8/5/98 Application 9809951.8 Binding molecule
  10. Atherton, A., Armour, K., & Clark, M.R. Priority date 28/10/99 Application 9925490.6 Binding molecules and treatment and screening methods
  11. Laukanen, M-L., Clark, M.R. et al Priority date 29/04/02 Application 20020807 (Finland) Novel humanized anti-vap-1 monoclonal antibody
  12. Armour, K., & Clark, M.R. Priority date 17/10/03 Application 0324368.0 (U.K.) Polypeptides including modified constant regions.

 Section D: Granted US Patents

In the biotechnology and biopharmaceutical sector the US is a major centre for commercial research, manufacturing and sales. Thus a crucial element for commercial development is to seek to obtain patent protection within the US. In prosecuting the following patents I have worked closely with attorneys in the UK and the USA and I have also made personal appearances in the US patent offices in Washington DC. The following is a list of granted US patents of which I am an inventor.

  1. Bolt,S., Clark,M.R., Gorman,S.D., Routledge,E.D.& Waldmann,H.
    US Patent 5,585,097 17/12/1996
    Humanized anti-CD3 specific antibodies
  2. Waldmann,H., Clark,M.R., Winter,G.P. & Riechmann,L.
    US Patent 5,846,534 8/12/1998
    Antibodies to the antigen Campath-1
  3. Waldmann,H., Clark,M.R., Winter,G.P. & Riechmann,L.
    US Patent 6,569,430 27/05/2003
    Antibodies to the antigen Campath-1
  4. Bolt,S., Clark,M.R., Gorman,S.D., Routledge,E.D.& Waldmann,H.
    US Patent 6,706,265 16/03/2004
    Humanized anti-CD3 specific antibodies
  5. Gorman,S.D., Clark,M.R., Cobbold,S.P., & Waldmann,H.
    US Patent 6,767,996 27/07/2004
    Altered antibodies and their preparation.
  6. Gorman,S.D., Clark,M.R., Cobbold,S.P., & Waldmann,H.
    US Patent 7,098,006 29/08/2006
    Chimeric antibody, pharmaceutical composition and process of its production
  7. Armour,K.L., Clark, M.R., & Williamson, L.M.
    US Patent 7,597,889 6/10/2009
    Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis

This page is from (Sig Picture Not Displayed) Mike Clark.
"An antibody engineer who also enjoys the mountains."
Mike's home-page
14th October 2010